Sharp HealthCare is a not-for-profit regional health care group located in San Diego. Sharp includes four acute-care hospitals, three specialty hospitals, three affiliated medical groups, and a healthcare plan. Sharp has approximately 2,600 physicians, and more than 18,000 employees..
Background:Rates of burnout and job dissatisfaction remain high among clinicians. While health care organizational changes are needed to promote their well-being, individual factors must also be supported. A key factor for health behavior change and well-being includes meaning, purpose and spirituality (MPS), among other lifestyle factors. Yet, clinician well-being programs are often lacking explicit support for MPS. Objective and Approach:To develop a synthesis of the evidence behind MPS in clinician well-being and report on the discussions of experts from a national summit on MPS on integrating MPS into clinician well-being programs. Findings:Addressing MPS as a key element of a comprehensive healthy lifestyle is vital for healthcare professionals and essential in targeted interventions to improve physical health and mental well-being, decrease burn out, and boost life satisfaction. Researchers and experts in MPS and in lifestyle medicine emphasize the essential role of MPS in well-being. Integrating MPS into daily life and fostering relationships that cultivate a sense of mattering in the workplace promote resilience and intrinsic motivation, help professionals reconnect with their purpose, ultimately advancing positive behavior and health across all career stages. Organizations can enhance well-being programs and foster well-being culture in the workplace that honors MPS. While research on clinician well-being has evolved, gaps remain in replicability, scalability and best practices of MPS interventions. Future studies should explore synergies between individual resources and systemic challenges to support MPS well-being factors. Conclusion:Further research and integration of MPS in clinician well-being programs is necessary in providing comprehensive approaches that address individual, as well as organizational and systemic factors.
Background and Aims: Traditionally, deep enteroscopy, surgery, or percutaneous biliary drains were used to gain access for biliary interventions in patients with Roux-en-Y reconstruction. These methods are cumbersome, less successful than standard ERCP, and carry a higher risk of adverse events (AEs). Transductal and transmural EUS-assisted techniques are increasingly used in these settings. Although EUS-directed transgastric ERCP is mainly used for Roux-en-Y gastric bypass, EUS-directed transenteric ERCP (EDEE) is used for Roux-en-Y hepaticojejunostomy (RYHJ) and Roux-en-Y gastrectomy. Methods: In this case series, we presented 3 patients who underwent EDEE for stones, strictures, or both. We highlighted the technical differences between RYHJ and Roux-en-Y gastrectomy, as well as the different methods to distend the targeted small-bowel loop. Results: The biliary orifice was easily reached, and biliary interventions were successfully performed in all patients using the necessary accessories. There were no AEs directly related to the procedures. Conclusions: EDEE is an important technique for biliary interventions in patients with nongastric bypass Roux-en-Y reconstruction. Further data are needed to assess its long-term effectiveness and safety.
Importance In trials targeting preclinical Alzheimer disease (AD), defined as amyloid pathology without cognitive symptoms, racial and ethnic differences in plasma phosphorylated tau 217 percentage (%p-tau217) may influence screening eligibility. Objective To characterize racial and ethnic differences in %p-tau217 and determine whether associations between %p-tau217, cognition, and amyloid positron emission tomography (PET) differ across groups. Design, Setting, and Participants This was a cross-sectional analysis of AHEAD 3-45 screening participants conducted from July 2020 to October 2024 at 106 sites across 4 world regions. Adults aged 55 to 80 years with %p-tau217 measured before medical and cognitive exclusions (N = 15 612) were included. Exposures Self-reported race (Asian, Black, and White) and ethnicity (Hispanic and non-Hispanic) and apolipoprotein E epsilon 4 (APOE epsilon 4) carrier status. Main Outcomes and Measures %p-tau217 levels and associations of %p-tau217 with Preclinical Alzheimer Cognitive Composite 5 (PACC5) score and amyloid PET were evaluated across racial and ethnic groups using multivariable linear regression. Results Among 15 612 participants, the mean (SD) age was 68.4 (6.2) years; 9941 (63.7%) were female and 5755 (36.9%) were APOE epsilon 4 carriers. %p-tau217 levels were lower among Asian, Black, and Hispanic participants than among White and non-Hispanic participants. APOE epsilon 4 status was associated with higher %p-tau217 across all groups. The association between APOE epsilon 4 status and %p-tau217 differed by race (APOE epsilon 4 & times; race: F-2,F-14 973 = 10.06; P < .001) and ethnicity (APOE epsilon 4 & times; ethnicity: beta, 0.042; 95% CI, 0.017 to 0.067; P = .005) (Asian: beta, 0.05; 95% CI, 0.02 to 0.08; P = .01; Black: beta, 0.05; 95% CI, 0.03 to 0.08; P = .002; Hispanic: beta, 0.04; 95% CI, 0.02 to 0.07; P = .005). The %p-tau217-PACC5 association showed no pairwise differences across racial groups but differed by ethnicity (beta, -0.53; 95% CI, -0.85 to -0.21; P = .008) and APOE epsilon 4 & times; ethnicity (beta, 0.78; 95% CI, 0.26 to 1.30; P = .02). The %p-tau217-PET association showed no significant pairwise differences across racial groups but differed by ethnicity (beta, -6.30; 95% CI, -9.10 to -3.51; P < .001) and APOE epsilon 4 & times; ethnicity (beta, 7.12; 95% CI, 2.52 to 11.73; P = .01). Conclusions and Relevance In this cross-sectional study, plasma %p-tau217 varied across racial and ethnic groups. Consistent %p-tau217-PACC5 score and %p-tau217-PET associations across racial groups support plasma-based screening before PET confirmation, while ethnicity-related findings warrant further investigation.